The collective findings from Section 3.4, Section 3.5 and Section 3.6 establish a consistent pattern: none of the three inflammatory markers (IL-6, hsCRP, TNF-α) demonstrated significant associations with liver disease severity across any of the five non-invasive fibrosis scoring systems (CAP, APRI, NAFLD-F, TE, FAST) or with cardiovascular risk assessment (ASCVD score). The gene discussed is IL6; the disease is metabolic dysfunction-associated steatotic liver disease.